Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
帕博利珠单抗联合化疗(加或不加贝伐珠单抗)治疗东亚持续性、复发性或转移性宫颈癌患者:KEYNOTE-826最终分析结果
期刊:Journal of Gynecologic Oncology
影响因子:3.7
doi:10.3802/jgo.2025.36.e110
Kim, Yong-Man; Nishio, Shin; Kim, Se Ik; Hasegawa, Kosei; Dubot, Coraline; Cáceres, M Valeria; Tewari, Krishnansu S; Lorusso, Domenica; Lee, Jeong-Won; Liou, Wen-Shiung; Li, Kan; Tekin, Cumhur; Colombo, Nicoletta; Monk, Bradley J